BridgeBio Pharma, Inc.

$68.91

$1.16(-1.65%)

BridgeBio Pharma, Inc.

BBIO

$68.91

$1.16(-1.65%)

BridgeBio Pharma, Inc.

BBIO

NASDAQ

$68.91

$1.16(-1.65%)

Chart

Upcoming Earnings

Next report date

May 5, 2026

Report period

Q2 2026

EPS Estimate

$-0.71

Revenue Estimate

—

Key stats

52-Week Range$68.91

$28.33

$84.94

Market capitalization

$13.77B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

-20.10

Basic EPS (TTM)

$-3.79

Net income (TTM)

$-729.31M

Revenue (TTM)

$502.08M

Avg. volume

2.92M

Beta (1Y)

1.18

Employees

725

Market capitalization

$13.77B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

-20.10

Basic EPS (TTM)

$-3.79

Net income (TTM)

$-729.31M

Revenue (TTM)

$502.08M

Avg. volume

2.92M

Beta (1Y)

1.18

Employees

725

Screener Quick Check

About BridgeBio Pharma, Inc.

Sector

Healthcare

Industry

Biotechnology

CEO

Neil Kumar

Website

www.bridgebio.com

Headquarters

421 Kipling Street, Palo Alto, CA, 94301

IPO Date

2019-06-27

Identifiers

ISINUS10806X1028

Description

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases....

Related Stocks

Moderna, Inc.

MRNA

$53.31Mkt Cap: $21.05B

Healthcare

Biotechnology

ISIN:US60770K1079

Roivant Sciences Ltd.

ROIV

$28.28Mkt Cap: $20.24B

Healthcare

Biotechnology

ISIN:BMG762791017

Dividend Overview

This company does not pay dividends

Financials

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate